Portrazza European Union - English - EMA (European Medicines Agency)

portrazza

eli lilly nederland b.v. - necitumumab - carcinoma, non-small-cell lung - antineoplastic agents - portrazza in combination with gemcitabine and cisplatin chemotherapy is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (egfr) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.

Orthosis, spinal, lumbosacral, corset, hernia/ptosis support Australia - English - Department of Health (Therapeutic Goods Administration)

orthosis, spinal, lumbosacral, corset, hernia/ptosis support

therapist support laboratory pty ltd - 41029 - orthosis, spinal, lumbosacral, corset, hernia/ptosis support - a garment made of elastic material designed to control and support the abdomen for hernias

APO-CICLOSPORIN ciclosporin 25 mg soft capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-ciclosporin ciclosporin 25 mg soft capsule blister pack

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 25 mg - capsule, soft - excipient ingredients: gelatin; iron oxide black; polysorbate 20; purified water; ethyl lactate; sorbitan oleate; titanium dioxide; peg-40 hydrogenated castor oil; glycerol; tricaprin; lecithin - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

APO-CICLOSPORIN ciclosporin 50 mg soft capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-ciclosporin ciclosporin 50 mg soft capsule blister pack

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 50 mg - capsule, soft - excipient ingredients: gelatin; titanium dioxide; tricaprin; sorbitan oleate; lecithin; purified water; ethyl lactate; polysorbate 20; iron oxide black; peg-40 hydrogenated castor oil; glycerol - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

APO-CICLOSPORIN ciclosporin 100 mg soft capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-ciclosporin ciclosporin 100 mg soft capsule blister pack

arrotex pharmaceuticals pty ltd - ciclosporin, quantity: 100 mg - capsule, soft - excipient ingredients: gelatin; iron oxide black; ethyl lactate; lecithin; polysorbate 20; glycerol; sorbitan oleate; purified water; tricaprin; peg-40 hydrogenated castor oil; titanium dioxide - ciclosporin is indicated: ? as an immunosuppressive agent for the prevention of graft rejection following kidney, liver and heart allogeneic transplantation. ? for induction and/or maintenance of remission in the nephrotic syndrome. ciclosporin is not a first-line agent. its use should be restricted to occasions when steroids and cytostatic drugs have failed, or are not tolerated, or are considered inappropriate, and when renal function is unimpaired (see section 4.4 special warnings and precautions for use). ? for the treatment of severe, active rheumatoid arthritis in patients for whom classical slow-acting antirheumatic agents (including methotrexate) are inappropriate or ineffective. ? in patients with severe psoriasis in whom conventional therapy is ineffective or inappropriate and the disease has caused a significant interference with quality of life. ? for the treatment of severe atopic dermatitis when other treatment is ineffective or inappropriate.,careful monitoring of all ciclosporin-treated patients is mandatory. ciclosporin should only be used by medical practitioners who are experienced in the use of immunosuppressive therapy (see section 4.4 special warnings and precautions for use).

Transport wheelchair, collapsible Australia - English - Department of Health (Therapeutic Goods Administration)

transport wheelchair, collapsible

etac anz pty ltd - 45052 - transport wheelchair, collapsible - transport wheelchair attendant driven collapsible

POR-8 FERRING ornipressin 5 I.U./mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

por-8 ferring ornipressin 5 i.u./ml injection ampoule

ferring pharmaceuticals pty ltd - ornipressin, quantity: 5 iu/ml - injection, solution - excipient ingredients: sodium acetate; glacial acetic acid; sodium chloride; water for injections - local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem plastic surgery: hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc obstetrics/gynaecology: vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy. ent surgery: tonsillectomy, submucous resection of septum, myringoplasty etc. other types of surgery: neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar).

Transport Swabs - General specimen transport medium collection kit Australia - English - Department of Health (Therapeutic Goods Administration)

transport swabs - general specimen transport medium collection kit

hurst & co pty ltd - 62773 - general specimen collection kit ivd, transport medium - transport swabs are intended for the collection of biological samples for subsequent microbiological analysis